Boehringer Ingelheim’s "China Key" strategy advances with launch of local Trajenta® production

On October 13, Boehringer Ingelheim announced the official launch of its localized production plan in China for the glucose-lowering drug Trajenta® (linagliptin, Chinese brand name: 欧唐宁®). This initiative will enhance the supply stability and resilience of Trajenta® in the Chinese market, further improve drug accessibility, and drive equipment upgrades and capacity optimization at the company's Shanghai-based human pharmaceuticals production base.

Hubertus von Baumbach, Chairman of the Shareholders' Committee of Boehringer Ingelheim, and Mohammed Tawil, President and CEO of Boehringer Ingelheim Greater China, along with other representatives, attended the launch ceremony held in Shanghai's Zhangjiang area.

Mohammed Tawil stated that as Boehringer Ingelheim marks its 30th anniversary in the Chinese market, the localization of Trajenta's production in Shanghai carries special significance. Over the past three decades, Boehringer Ingelheim has consistently grown in tandem with China's development. Looking ahead, the company will continue to leverage the speed, scale, and influence of the Chinese market to deepen its local roots while serving global needs, accelerating the delivery of innovative solutions to patients and animals worldwide.

It is reported that Boehringer Ingelheim continues to deepen its "China Key" strategy, increasing investment in the country to establish a full-value-chain layout encompassing early-stage R&D, clinical development, manufacturing, commercialization, and external innovation partnerships. Over the next five years, the company plans to invest over RMB 5 billion in R&D in China. The human pharmaceuticals pipeline will focus on metabolic disorders, inflammation, eye health, and oncology. The animal health business will accelerate innovation in animal vaccine development and introduce globally leading innovative products. Furthermore, Boehringer Ingelheim remains committed to open innovation, collaborating with partners to build an innovation ecosystem. Through cross-border research, business development, licensing, and venture capital investments, the company continues to enrich its R&D pipeline.

While serving the Chinese market, Boehringer Ingelheim's human pharmaceutical and animal health production bases in China have evolved into supply hubs serving regional and global markets, with products distributed to Australia, New Zealand, Singapore, and other countries and regions. The Nanchang animal health facility has been upgraded to a global production base, achieving stable supply to multiple countries including Brazil and Argentina.